Physician profile
Antonio Duran
NPI 1588027700
$34,448.55
in general payments reported to CMS, 2019-2025
40 companies · $11K in 2025
The $11K reported for 2025 was more than what 78% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $339 · 2020: $538 · 2021: $3,828 · 2022: $16K · 2023: $1,287 · 2024: $1,701 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,083 · Food and Beverage: $4,789 · Education: $1.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,082.50 |
| Food and Beverage | $4,789.13 |
| Education | $1.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $17,895.24 | 2019-2025 | Cardiomems, Mitraclip |
| Bridgebio Pharma, INC. | $9,145.73 | 2025 | Attruby |
| Janssen Pharmaceuticals, INC | $884.66 | 2020-2023 | Xarelto |
| Abiomed | $879.23 | 2019-2025 | Impella |
| Astrazeneca Pharmaceuticals LP | $688.11 | 2019-2025 | Wainua, Brilinta, Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $654.98 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $648.27 | 2020-2025 | Camzyos, Eliquis |
| Alnylam Pharmaceuticals INC. | $383.14 | 2023-2025 | Amvuttra |
| Boston Scientific Corporation | $344.63 | 2021-2024 | Lux-Dx Insertable Cardiac Monitor, Watchman Flx |
| Pfizer INC. | $289.86 | 2020-2025 | |
| Edwards Lifesciences Corporation | $273.56 | 2024-2025 | Sapien 3 Ultra Resilia, Evoque |
| Daiichi Sankyo INC. | $261.81 | 2024-2025 | Injectafer |
| Novartis Pharmaceuticals Corporation | $260.35 | 2021-2025 | |
| Kestra Medical Technology Services, INC. | $245.67 | 2022 | |
| Astellas Pharma US INC | $194.34 | 2021 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $137.60 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $118.14 | 2019-2025 | Verquvo |
| Esperion Therapeutics, INC. | $111.90 | 2020-2021 | |
| Novo Nordisk INC | $102.38 | 2024-2025 | Rybelsus, Ozempic |
| Medtronic, INC. | $96.84 | 2021-2022 | |
| Scpharmaceuticals INC. | $90.07 | 2024 | |
| Cvrx, INC. | $73.19 | 2025 | Barostim Neo System |
| Cleerly, INC. | $71.60 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Irhythm Technologies, INC. | $67.49 | 2024 | Zio Xt Patch, Zio Monitor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.85 | 2024-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $66.09 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $64.95 | 2024 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $54.94 | 2021-2024 | Opsumit, Uptravi |
| Lexicon Pharmaceuticals, INC. | $43.45 | 2024 | |
| Inspire Medical Systems, INC. | $39.41 | 2025 | Inspire |
| Kiniksa Pharmaceuticals, LTD. | $24.94 | 2023 | Arcalyst |
| Lilly USA, LLC | $24.56 | 2025 | Zepbound |
| Lantheus Medical Imaging, INC. | $24.28 | 2019 | |
| Baxter Healthcare | $23.74 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Endotronix, INC. | $19.84 | 2021 | |
| Analog Devices INC. | $19.62 | 2024 | Sensinel Cpm Wearable |
| Biotronik INC. | $15.41 | 2021 | |
| Cook Medical LLC | $14.87 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.80 | 2021 | |
| Livanova USA, INC. | $13.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonio Duran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.